FDA grants approval to Regeneron Pharmaceuticals’ EYLEA HD injection

21 Aug 2023
www.pharmaceutical-technology.com
Drug ApprovalClinical Result
FDA grants approval to Regeneron Pharmaceuticals’ EYLEA HD injection
Preview
Source: Pharmaceutical Technology
EYLEA HD is indicated for the treatment of wet age-related macular degeneration. Credit: Image Point Fr/Shutterstock.com.
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ EYLEA HD 8mg injection (0.07mL of 114.3mg/mL solution).
Recommended Reports
FDA grants approval to Regeneron Pharmaceuticals’ EYLEA HD injection
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ensartinib Hydrochloride in Sarcomas GlobalData
FDA grants approval to Regeneron Pharmaceuticals’ EYLEA HD injection
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Pazopanib Hydrochloride in Gliosarcoma GlobalData
View allCompanies IntelligenceBayer AGDME CorporationPhoton, Inc.Regeneron GmbHPulsar LLCView all
The recommended dose across all indications is EYLEA HD 8mg every four weeks for the initial three months.
EYLEA HD is then given every eight to 16 weeks in wAMD and DME and every eight to 12 weeks for DR.
The approval is based on two active-controlled, double-masked pivotal trials, PULSAR in wAMD and PHOTON in DME.
Bayer is the lead sponsor for PULSAR and Regeneron for PHOTON.
Conducted in multiple centres worldwide, these studies compared EYLEA HD to EYLEA (aflibercept) injection 2mg for 48 weeks.
Patients who received EYLEA HD in both trials had three initial monthly doses while those treated with EYLEA received three initial doses of PULSAR and five of PHOTON.
Both PULSAR in wAMD (N=1,009) and PHOTON in DME (N=658) met their primary endpoint demonstrating non-inferior and clinically equivalent vision gains with EYLEA HD.
The majority of patients randomised at baseline to EYLEA HD 12 or 16-week dosing regimens also maintained these dosing intervals through the 48-week period.
The most common adverse reactions reported in patients treated with EYLEA HD were increased intraocular pressure, conjunctival haemorrhages and cataracts.
Regeneron chief scientific officer, president, board co-chair and EYLEA principal inventor George Yancopoulos stated: “Our continued commitment to retinal diseases resulted in an important scientific innovation – evolving the proven efficacy and safety of EYLEA into a new treatment, EYLEA HD, that provides lasting vision control with even fewer injections to further benefit those living with wet age-related macular degeneration or diabetic retinal diseases.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.